Quantcast

Latest Ibritumomab tiuxetan Stories

2009-01-08 00:30:00

SEATTLE, Jan. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that they received $7.5 million pursuant to the joint venture transaction with Spectrum Pharmaceuticals, Inc. to commercialize and develop Zevalin(R) in the United States.

2008-12-16 00:30:00

SEATTLE, Dec. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.(CTI) (Nasdaq and MTA: CTIC) announced today they have closed the transaction with Spectrum Pharmaceuticals, Inc.

2008-12-04 00:30:00

SEATTLE, Dec. 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.

2008-12-01 00:30:00

SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- On Monday, December 1, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m.

2008-12-01 00:30:00

SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S.

2008-11-13 03:00:16

Cell Therapeutics, a biopharmaceutical company, has achieved the primary efficacy endpoint of its Phase III Extend trial of pixantrone for patients with advanced, relapsed aggressive non-Hodgkin's lymphoma based on a preliminary intent to treat efficacy analysis.

2008-11-11 03:00:09

SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.

2008-11-04 06:00:10

Having gained approval as a treatment for chronic lymphocytic leukemia earlier this year, the FDA has now extended Treanda's use to indolent B-cell non-Hodgkin's lymphoma.

2008-11-03 09:00:40

Cell Therapeutics, a biopharmaceutical company, has closed the data set for preliminary analysis of the primary endpoint in the Phase III Extend trial of pixantrone for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma. It has also notified Novartis that the data set has been closed.


Word of the Day
gubbings
  • The parings of haberdine; also, any kind of fragments.
The word 'gubbings' is a variant of the word 'gobbon', meaning 'a portion, gobbet.'